ProfileGDS5678 / 1415754_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 90% 89% 90% 89% 88% 88% 88% 88% 89% 88% 88% 88% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6549587
GSM967853U87-EV human glioblastoma xenograft - Control 27.204590
GSM967854U87-EV human glioblastoma xenograft - Control 37.0186489
GSM967855U87-EV human glioblastoma xenograft - Control 47.3224190
GSM967856U87-EV human glioblastoma xenograft - Control 57.0652289
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5342488
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7123688
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8454988
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8824588
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1007289
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7920288
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.988288
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.835888
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.8390488